Systematic review and meta-Analysis of circulating S100B blood levels in schizophrenia

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Aleksovska, Katina ^a   Leoncini, Emanuele ^a   Bonassi, Stefano ^b   Cesario, Alfredo ^b   Boccia, Stefania ^a   Frustaci, Alessandra ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; PROTEIN S100B; S100B PROTEIN, HUMAN;

BLOOD LEVEL; CASE CONTROL STUDY; DATA ANALYSIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE MARKER; DRUG RESPONSE; ETHNICITY; HUMAN; META ANALYSIS; MOLECULAR PATHOLOGY; PROTEIN DETERMINATION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW; BLOOD;

HUMANS; S100 CALCIUM BINDING PROTEIN BETA SUBUNIT; SCHIZOPHRENIA;

EID: 84924317414     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106342     Document Type: Review

References (78)

1. Rothermundt M, Ponath G, Glaser T, Hetzel G, Arolt V (2004) S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia. Neuropsychopharmacology 29: 1004-11.
2. Steiner J, Bernstein HG, Bielau H, Annika B, Brisch R, et al. (2007) Evidence for a wide extra-astrocytic distribution of S100B in human brain. BMC Neurosci 8: 2.
3. Steiner J, Myint AM, Schiltz K, Westphal S, Bernstein HG, et al. (2010) S100B Serum levels in schizophrenia are presumably related to visceral obesity and insulin resistance. Cardiovasc Psychiatry Neurol 2010: 480-707.
4. Michetti F, Corvino C, Geloso MC, Lattanzi W, Bernardini C, et al. (2012) The S100B protein in biological fluids: More than a lifelong biomarker of brain distress. J Neurochem 120: 644-59.
5. Donato R (2007) RAGE: A single receptor for several ligands and different cellular responses: The case of certain S100 proteins. Curr Mol Med 7: 711-24.
6. Businaro R, Leone S, Fabrizi C, Sorci G, Donato R, et al. (2006) S100B protects LAN-5 neuroblastoma cells against Abeta amyloid-induced neurotoxicity via RAGE engagement at low doses but increases Abeta amyloid neurotoxicity at high doses. J Neurosci Res 83: 897-906.
7. Sorci G, Riuzzi F, Arcuri C, Tubaro C, Bianchi R, et al. S100B protein in tissue development, repair and regeneration. World J Biol Chem 4: 1-12.
8. Kleindienst A, Hesse F, Bullock MR, Buchfelder M (2007) The neurotrophic protein S100B: value as a marker of brain damage and possible therapeutic implications. Prog Brain Res 161: 317-25.
9. Gonçalves CA, Leite MC, Nardin P (2008) Biological and methodological features of the measurement of S100B, a putative marker of brain injury. Clin Biochem 41: 755-63.
10. Mercier E, Boutin A, Lauzier F, Fergusson DA, Simard JF, et al. (2013) Predictive value of S-100b protein for prognosis in patients with moderate and severe traumatic brain injury: Systematic review and meta-analysis. BMJ 4: 346:f1757.
11. de Souza DF, Wartchow K, Hansen F, Lunardi P, Guerra MC, et al. (2013) Interleukin-6-induced S100B secretion is inhibited by haloperidol and risperidone. Prog Neuropsychopharmacol. Biol Psychiatry 43: 14-22.
12. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, et al. (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21: 383-421.
13. Gárate I, García-Bueno B, Madrigal JL, Bravo L, Berrocoso E, et al. (2011) Origin and consequences of brain toll-like receptor 4 pathway stimulation in an experimental model of depression. J Neuroinflammation 8: 151.
14. Monji A, Kato T, Kanba S (2009) Cytokines and schizophrenia: Microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci 63: 257-65.
15. Khansari N, Shakiba Y, Mahmoudi M (2009) Chronic inflammation and oxidative stress as a major cause of age-related diseases and cancer. Recent Patents Inflamm Allergy Drug Discov 3: 73-80.
16. Ashe PC, Berry MD, Boulton AA (2001) Schizophrenia, a neurodegenerative disorder with neurodevelopmental antecedents. Prog Neuropsychophamacol Biol Psychiatry 25: 691-707.
17. Raedler TJ, Knable MB, Weinberger DR (1998) Schizophrenia as a developmental disorder of the cerebral cortex. Curr Opin Neurobiol 8: 157- 161.
18. Altamura AC, Pozzoll S, Fiorentini A, Dell'Osso B (2013) Neurodevelopment and inflammatory patterns in schizophrenia in relation to pathophysiology. Prog Neuropsychopharmacol Biol Psychiatry 42: 63-70.
19. Anderson G, Berk M, Dodd S, Bechter K, Altamura AC, et al. (2013) Immunoinflammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course and treatment of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 42: 1-4.
20. Mondelli V, Howes O (2014) Inflammation: Its role in schizophrenia and the potential anti-inflammatory effects of antipsychotics. Psychopharmacology (Berl) 231: 317-8.
21. Durany N, Thome J (2004) Neurotrophic factors and the pathophysiology of schizophrenic psychoses. Eur. Psychiatr 19: 326-337.
22. Liu J, Shi Y, Tang J, Guo T, Li X, et al. (2005) SNPs and haplotypes in the S100B gene reveal association with schizophrenia. Biochem Biophys Res Commun 328: 335-41.
23. Schroeter ML, Abdul-Khaliq H, Krebs M, Diefenbacher A, Blasig IE (2009) Neuron-specific enolase is unaltered whereas S100B is elevated in serum of patients with schizophrenia-original research and meta-analysis. Psychiatry Res 167: 66-72.
24. Schroeter ML, Steiner J (2009) Elevated serum levels of the glial marker protein S100B are not specific for schizophrenia or mood disorders. Mol Psychiatry 14: 235-7.
25. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, et al. The Newcastle- Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in metaanalyses. Available: http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp. Accessed: 2014 Apr 8.
26. Deeks JJ, Altman DG, Bradburn MJ (2008) Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In Altman DG, Bradburn MJ, editors. Systematic Reviews in Health Care: Meta- Analysis in Context. 2nd ed. London, UK: BMJ Publishing Group.pp. 285-312.
27. Friedrich JO, Adhikari NK, Beyene J (2011) Ratio of means for analyzing continuous outcomes in meta-analysis performed as well as mean difference methods. J Clin Epidemiol 64: 556-64.
28. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-88.
29. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-34.
30. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. Ital J Public Health 4: 354-391.
31. Steiner J, Myint AM, Schiltz K, Westphal S, Bernstein HG, et al. (2010) S100B Serum levels in schizophrenia are presumably related to visceral obesity and insulin resistance. Cardiovasc Psychiatry Neurol 15: 3-4.
32. Steiner J, Walter M, Guest P, Myint AM, Schiltz K, et al (2010) Elevated S100B levels in schizophrenia are associated with insulin resistance. Mol Psychiatry 15: 3-4.
33. Steiner J, Westphal S, Schroeter ML, Schiltz K, Jordan W, et al. (2012) Increased S100B+ NK cell counts in acutely ill schizophrenia patients are correlated with the free cortisol index, but not with S100B serum levels. Brain Behav Immun 26: 564-7.
34. Zhang XY, Xiu MH, Chen da C, Zhu FY, Wu GY, et al. (2010) Increased S100B serum levels in schizophrenic patients with tardive dyskinesia: Association with dyskinetic movements. J Psychiatr Res 44: 429-33.
35. Falcone T, Carlton E, Lee C, Janigro M, Fazio V, et al. (2013) Does systemic inflammation play a role in pediatric psychosis? Clin Schizophr Relat Psychoses 14: 1-43.
36. Gattaz WF, Lara DR, Elkis H, Portela LV, Gonçalves CA, et al. (2000). Decreased S100-beta protein in schizophrenia: Preliminary evidence. Schizophr Res 43: 91-5.
37. Lara DR, Gama CS, Belmonte-de-Abreu P, Portela LV, Gonçalves CA, et al. (2001) Increased serum S100B protein in schizophrenia: A study in medicationfree patients. J Psychiatr Res 35: 11-4.
38. Ling SH, Tang YL, Jiang F, Wiste A, Guo SS, et al. (2007) Plasma S-100B protein in Chinese patients with schizophrenia: comparison with healthy controls and effect of antipsychotics treatment. J Psychiatr Res 41: 36-42.
39. O'Connell K, Thakore J, Dev KK (2013). Levels of S100B are raised in female patients with schizophrenia. BMC Psychiatry 13: 146.
40. Qi LY, Xiu MH, Chen da C, Wang F, Kosten TA, et al. (2009) Increased serum S100B levels in chronic schizophrenic patients on long-term clozapine or typical antipsychotics. Neurosci Lett 462: 113-7.
41. Rothermundt M, Missler U, Arolt V, Peters M, Leadbeater J, et al (2001) Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology. Mol Psychiatry 6: 445-9.
42. Rothermundt M, Ponath G, Glaser T, Hetzel G, Arolt V (2004) S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia. Neuropsychopharmacology 29: 1004-11.
43. Rothermundt M, Falkai P, Ponath G, Abel S, Bü rkle H, et al. (2004) Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF. Mol Psychiatry 9: 897-9.
44. Rothermundt M, Ohrmann P, Abel S, Siegmund A, Pedersen A, et al. (2007) Glial cell activation in a subgroup of patients with schizophrenia indicated by increased S100B serum concentrations and elevated myo-inositol. Prog Neuropsychopharmacol Biol Psychiatry. 31: 361-4.
45. Ryoun Kim H, Kyung Lee M, Park DB (2007) Increased serum S100B protein in chronic schizophrenic patients in Korea. Clin Chem Lab Med 45: 1561-3.
46. Sarandol A, Kirli S, Akkaya C, Altin A, Demirci M, et al. (2007) Oxidativeantioxidative systems and their relation with serum S100 B levels in patients with schizophrenia: Effects of short term antipsychotic treatment. Prog Neuropsychopharmacol Biol Psychiatry 31: 1164-9.
47. Schmitt A, Bertsch T, Henning U, Tost H, Klimke A, et al. (2005) Increased serum S100B in elderly, chronic schizophrenic patients: negative correlation with deficit symptoms. Schizophr Res 80: 305-13.
48. Schroeter ML, Abdul-Khaliq H, Frühauf S, Höhne R, Schick G, et al. (2003) Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia. Schizophr Res 62: 231-6.
49. Schroeter ML, Abdul-Khaliq H, Krebs M, Diefenbacher A, Blasig IE (2009) Neuron-specific enolase is unaltered whereas S100B is elevated in serum of patients with schizophrenia-original research and meta-analysis. Psychiatry Res 167: 66-72.
50. Steiner J, Bielau H, Bernstein HG, Bogerts B, Wunderlich MT (2006) Increased cerebrospinal fluid and serum levels of S100B in first-onset schizophrenia are not related to a degenerative release of glial fibrillar acidic protein, myelin basic protein and neurone-specific enolase from glia or neurones. J Neurol Neurosurg Psychiatry 77: 1284-7.
51. Steiner J, Walter M, Wunderlich MT, Bernstein HG, Panteli B, et al. (2009). A new pathophysiological aspect of S100B in schizophrenia: Potential regulation of S100B by its scavenger soluble RAGE. Biol Psychiatry 65: 1107-10.
52. Uzbay T, Goktalay G, Kayir H, Eker SS, Sarandol A, et al (2013) Increased plasma agmatine levels in patients with schizophrenia. J Psychiatr Res 47: 1054- 60.
53. van der Leeuw C, Marcelis M, Peeters SC, Verbeek MM, Menheere PP, et al. (2013) Replicated evidence of absence of association between serum S100B and (risk of) psychotic disorder. PLoS One 8: E82535.
54. Wiesmann M, Wandinger KP, Missler U, Eckhoff D, Rothermundt M, et al. (1999) Elevated plasma levels of S-100b protein in schizophrenic patients. Biol Psychiatry 45: 1508-11.
55. Zhang XY, Xiu MH, Song C, Chen da C, Wu GY, et al. (2010) Increased serum S100B in never-medicated and medicated schizophrenic patients. J Psychiatr Res 44: 1236-40.
56. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Washington, DC: American Psychiatric Association.
57. American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders. 4th edition, text revised. Washington, DC: American Psychiatric Association.
58. World Health Organization (1992) International Statistical Classification of Diseases and Related Health Problems, Tenth Revision. Geneva: World Health Organization.
59. Andreasen NC, Grove WM (1986) Evaluation of positive and negative symptoms in schizophrenia. Psychiatry and Psychobiology 1: 108-121.
60. Andreasen NC (1982) Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry 39: 784-8.
61. Iager AC, Kirch DG, Wyatt RJ (1985) A negative symptom rating scale. Psychiatry Res 16: 27-36.
62. Kay SR, Fiszbein A, Opler LA (1987) The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bull 13: 261.
63. Overall JE, Gorham DR (1962) The Brief Psychiatric Rating Scale. Psychological Reports 10: 799-812.
64. Addington D, Addington J, Maticka-Tyndale E (1993) Assessing depression in schizophrenia: The Calgary Depression Scale. Br J Psychiatry Suppl 22: 39-44.
65. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiat 23: 56.
66. Yelmo-Cruz S, Morera-Fumero AL, Abreu-González P 2013) S100B and schizophrenia. Pychiatry Clin Neurosci 67: 67-75.
67. Kirpatrick B, Buchanan RW, Ross DE, Carpenter WT (2001) A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry 58: 165-171.
68. Pedersen A, Diedrich M, Kaestner F, Koelkebeck K, Ohrmann P, et al. (2008) Memory impairment correlates with increased S100B serum concentrations in patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 32: 1789-92.
69. Fulle S, Pietrangelo T, Mariggiò MA, Lorenzon P, Racanicchi L, et al. (2000) Calcium and fos involvement in brain-derived Ca(2+)-binding protein (S100)- dependent apoptosis in rat phaeochromocytoma cells. Exp Physiol 85: 243-53.
70. Grubb NR, Simpson C, Sherwood RA, Abraha HD, Cobbe SM, et al. (2007) Prediction of cognitive dysfunction after resuscitation from out-of-hospital cardiac arrest using serum neuron-specific enolase and protein S-100. Heart 93: 1268-73.
71. Buschert J, Hohoff C, Touma C, Palme R, Rothermundt M, et al. (2013) S100B overexpression increases behavioral and neural plasticity in response to the social environment during adolescence. J Psychiatr Res: 1791-9.
72. Streitbürger DP, Arelin K, Kratzsch J, Thiery J, Steiner J, et al. (2012) Validating serum S100B and neuron-specific enolase as biomarkers for the human brain - A combined serum, gene expression and MRI study. PLoS One 7:e43284.
73. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available: Www.cochrane-handbook.org.
74. Hayashi-Takagi A, Vawter MP, Iwamoto K (2014) Peripheral biomarkers revisited: Integrative profiling of peripheral samples for psychiatric research. Biol Psychiatry 75: 920-8.
75. Weickert CS, Weickert TW, Pillai A, Buckley PF (2013) Biomarkers in schizophrenia: A brief conceptual consideration. Dis Markers 35: 3-9.
76. Bousquet J, Anto JM, Sterk PJ, Adcock IM, Chung KF, et al. (2011) Systems medicine and integrated care to combat chronic non communicable diseases. Genome Med 3: 4.
77. Cesario A, Auffray C, Agusti A, Apolone G, Balling R, et al. (2014) A Systems Medicine clinical platform for understanding and management of Non- Communicable Diseases. Curr Pharm Des Mar 14. [Epub ahead of print].
78. Flores M, Glusman G, Brogaard K, Price ND, Hood L (2013) P4 medicine: how systems medicine will transform the healthcare sector and society. Personalized Medicine 10: 565-576.